EGFR and non-small cell lung carcinoma: Osimertinib showed better ORR than chemotherapy in the phase III AURA3 study (intracranial ORR: 70% with osimertinib vs. 31% with platinum plus pemetrexed in patients with previously treated T790M positive NSCLC, p = 0.015) and 1G EGFR-TKIs in a phase III FLAURA study (intracranial ORR: 66% with osimertinib versus 43% with standard EGFR-TKIs in patients with untreated EGFR-mutated NCLC, p = 0.011) [29].